EGM
MNPR icon

Engineers Gate Manager’s Monopar Therapeutics MNPR Stock Holding History

Engineers Gate Manager’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$322K Sell
3,479
-955
-22% -$59.1K ﹤0.01% 1744
2026
Q1 		$243K Buy
4,434
+96
+2% +$5.8K ﹤0.01% 1819
2025
Q4 		$283K Buy
+4,338
New +$354K ﹤0.01% 1660

Other funds holding MNPR

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Engineers Gate Manager's MNPR Position: Q2 2026 in Review

Engineers Gate Manager reduced its Monopar Therapeutics (MNPR) stake by 22% in Q2 2026, selling an estimated $59.1K and leaving 3,479 shares worth $322K. The position accounts for ﹤0.01% of the portfolio, ranked #1744.

Engineers Gate Manager first reported a position in MNPR in Q4 2025 and has held it in 3 quarters since. 96 funds tracked by Wall St. Rank hold MNPR as of Q2 2026.

  • Engineers Gate Manager held 3,479 shares of Monopar Therapeutics worth $322K as of Q2 2026.
  • Engineers Gate Manager sold 955 Monopar Therapeutics shares in Q2 2026, an estimated $59.1K.
  • Monopar Therapeutics made up ﹤0.01% of Engineers Gate Manager's portfolio in Q2 2026, its #1744 holding.
  • Engineers Gate Manager first reported a position in Monopar Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 96 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q2 2026.

Based on Engineers Gate Manager's 13F filing for Q2 2026, filed 14 Aug 2026.